Soda, H., Maeda, H., Hasegawa, J., Takahashi, T., Hazama, S., Fukunaga, M., . . . Mishima, H. (2015). Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer.
Dyfyniad Arddull ChicagoSoda, Hitoshi, et al. "Multicenter Phase II Study of FOLFOX or Biweekly XELOX and Erbitux (cetuximab) As First-line Therapy in Patients With Wild-type KRAS/BRAF Metastatic Colorectal Cancer: The FLEET Study." BMC Cancer 2015.
Dyfyniad MLASoda, Hitoshi, et al. "Multicenter Phase II Study of FOLFOX or Biweekly XELOX and Erbitux (cetuximab) As First-line Therapy in Patients With Wild-type KRAS/BRAF Metastatic Colorectal Cancer: The FLEET Study." BMC Cancer 2015.